Oramed Pharmaceuticals’ (ORMP) Neutral Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Oramed Pharmaceuticals (NASDAQ:ORMP – Free Report) in a research note issued to investors on Monday, Benzinga reports. HC Wainwright also issued estimates for Oramed Pharmaceuticals’ Q3 2024 earnings at ($0.02) EPS, Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at $0.17 EPS, Q1 2025 earnings at […]